Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Micro-dosed Psilocybin for Anxiety and Depression
NCT04989972Phase 2Withdrawn
- Sponsor
- Wake Network
- Start
- Sep 2022
- Primary completion
- Jun 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in anxiety disorder, major depressive disorder (MDD), sponsored by Wake Network. Planned start Sep 2022; status: withdrawn.
02
Drugs
psilocybin
03
Conditions
anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04989972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04989972.